Clinical Trial Update: ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports the evaluation of ANDES-AGI-1067 as a novel antidiabetic agent in Phase 2 and Phase 3 studies for diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• ANDES-AGI-1067

Snippet

Sponsor: AtheroGenics | Conditions: Diabetes | Phase 2, Phase 3 | Status: UNKNOWN